Hubei Jumpcan Pharmaceutical Co Ltd

SHG:600566 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.33 Billion
CN¥24.44 Billion CNY
Market Cap Rank
#6545 Global
#1006 in China
Share Price
CN¥26.53
Change (1 day)
-0.34%
52-Week Range
CN¥24.32 - CN¥28.97
All Time High
CN¥44.43
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more

Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Net Assets

Latest net assets as of September 2025: CN¥13.86 Billion CNY

Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has net assets worth CN¥13.86 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥16.53 Billion) and total liabilities (CN¥2.68 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥13.86 Billion
% of Total Assets 83.82%
Annual Growth Rate 20.79%
5-Year Change 89.7%
10-Year Change 442.84%
Growth Volatility 49.37

Hubei Jumpcan Pharmaceutical Co Ltd - Net Assets Trend (1998–2024)

This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2024)

The table below shows the annual net assets of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2024.

Year Net Assets Change
2024-12-31 CN¥14.73 Billion +10.15%
2023-12-31 CN¥13.37 Billion +17.76%
2022-12-31 CN¥11.35 Billion +24.33%
2021-12-31 CN¥9.13 Billion +17.62%
2020-12-31 CN¥7.76 Billion +27.17%
2019-12-31 CN¥6.10 Billion +11.85%
2018-12-31 CN¥5.46 Billion +23.99%
2017-12-31 CN¥4.40 Billion +19.37%
2016-12-31 CN¥3.69 Billion +35.93%
2015-12-31 CN¥2.71 Billion +18.26%
2014-12-31 CN¥2.29 Billion +99.06%
2013-12-31 CN¥1.15 Billion +134.80%
2012-12-31 CN¥490.80 Million -6.84%
2011-12-31 CN¥526.82 Million +1.26%
2010-12-31 CN¥520.27 Million +1.45%
2009-12-31 CN¥512.85 Million +1.32%
2008-12-31 CN¥506.18 Million +1.47%
2007-12-31 CN¥498.83 Million +2.68%
2006-12-31 CN¥485.82 Million +1.16%
2005-12-31 CN¥480.25 Million +1.34%
2004-12-31 CN¥473.92 Million +1.60%
2003-12-31 CN¥466.47 Million +1.62%
2002-12-31 CN¥459.05 Million +2.11%
2001-12-31 CN¥449.57 Million +221.10%
2000-12-31 CN¥140.01 Million +11.59%
1999-12-31 CN¥125.46 Million +15.70%
1998-12-31 CN¥108.44 Million --

Equity Component Analysis

This analysis shows how different components contribute to Hubei Jumpcan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 222898.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥10.18 Billion 69.27%
Common Stock CN¥452.69 Million 3.08%
Other Components CN¥4.07 Billion 27.65%
Total Equity CN¥14.70 Billion 100.00%

Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Bitfarms Ltd
NASDAQ:BITF
 		$1.21 Billion
Chengdu Xingrong Investment Co Ltd
SHE:000598
 		$1.21 Billion
STORSKOGEN GROUP AB SER.B
F:0VK
 		$1.21 Billion
Sandy Spring Bancorp Inc
NASDAQ:SASR
 		$1.21 Billion
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
 		$1.21 Billion
City Developments Ltd
PINK:CDEVY
 		$1.21 Billion
Ningbo Boway Alloy Material Co Ltd
SHG:601137
 		$1.21 Billion
Seaboard Corporation
NYSE MKT:SEB
 		$1.21 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hubei Jumpcan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 13,349,441,189 to 14,701,852,749, a change of 1,352,411,560 (10.1%).
  • Net income of 2,531,554,061 contributed positively to equity growth.
  • Dividend payments of 1,195,861,455 reduced retained earnings.
  • Share repurchases of 22,182,757 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥2.53 Billion +17.22%
Dividends Paid CN¥1.20 Billion -8.13%
Share Repurchases CN¥22.18 Million -0.15%
Other Changes CN¥38.90 Million +0.26%
Total Change CN¥- 10.13%

Book Value vs Market Value Analysis

This analysis compares Hubei Jumpcan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.66x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 33.77x to 1.66x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 CN¥0.79 CN¥26.53 x
1999-12-31 CN¥0.91 CN¥26.53 x
2000-12-31 CN¥1.01 CN¥26.53 x
2001-12-31 CN¥3.26 CN¥26.53 x
2002-12-31 CN¥3.32 CN¥26.53 x
2003-12-31 CN¥3.37 CN¥26.53 x
2004-12-31 CN¥3.43 CN¥26.53 x
2005-12-31 CN¥3.47 CN¥26.53 x
2006-12-31 CN¥3.51 CN¥26.53 x
2007-12-31 CN¥3.60 CN¥26.53 x
2008-12-31 CN¥3.65 CN¥26.53 x
2009-12-31 CN¥4.81 CN¥26.53 x
2010-12-31 CN¥3.75 CN¥26.53 x
2011-12-31 CN¥3.81 CN¥26.53 x
2012-12-31 CN¥0.80 CN¥26.53 x
2013-12-31 CN¥1.89 CN¥26.53 x
2014-12-31 CN¥2.96 CN¥26.53 x
2015-12-31 CN¥3.42 CN¥26.53 x
2016-12-31 CN¥4.58 CN¥26.53 x
2017-12-31 CN¥5.43 CN¥26.53 x
2018-12-31 CN¥6.69 CN¥26.53 x
2019-12-31 CN¥7.49 CN¥26.53 x
2020-12-31 CN¥9.30 CN¥26.53 x
2021-12-31 CN¥10.14 CN¥26.53 x
2022-12-31 CN¥12.48 CN¥26.53 x
2023-12-31 CN¥14.57 CN¥26.53 x
2024-12-31 CN¥16.03 CN¥26.53 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hubei Jumpcan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 17.22%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 31.58%
  • • Asset Turnover: 0.43x
  • • Equity Multiplier: 1.26x
  • Recent ROE (17.22%) is above the historical average (14.51%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1998 9.80% 16.33% 0.35x 1.72x CN¥-216.00K
1999 13.57% 20.77% 0.42x 1.57x CN¥4.48 Million
2000 10.39% 14.87% 0.44x 1.60x CN¥545.98K
2001 3.94% 15.53% 0.20x 1.30x CN¥-27.26 Million
2002 3.03% 12.95% 0.18x 1.33x CN¥-31.92 Million
2003 1.59% 6.53% 0.17x 1.40x CN¥-39.15 Million
2004 1.57% 5.08% 0.21x 1.48x CN¥-39.87 Million
2005 1.76% 4.79% 0.24x 1.53x CN¥-39.50 Million
2006 2.01% 4.85% 0.26x 1.62x CN¥-38.76 Million
2007 2.18% 4.98% 0.27x 1.61x CN¥-38.91 Million
2008 1.66% 3.93% 0.26x 1.64x CN¥-42.13 Million
2009 1.51% 3.47% 0.27x 1.63x CN¥-43.47 Million
2010 1.63% 3.57% 0.27x 1.66x CN¥-43.46 Million
2011 1.51% 3.29% 0.25x 1.83x CN¥-44.66 Million
2012 48.54% 12.38% 1.93x 2.03x CN¥188.70 Million
2013 34.95% 16.45% 1.22x 1.75x CN¥287.48 Million
2014 22.64% 17.39% 0.89x 1.46x CN¥289.99 Million
2015 25.73% 18.22% 1.05x 1.34x CN¥419.77 Million
2016 25.54% 19.97% 0.94x 1.36x CN¥568.45 Million
2017 27.79% 21.68% 0.85x 1.51x CN¥783.28 Million
2018 30.93% 23.42% 0.92x 1.43x CN¥1.14 Billion
2019 26.59% 23.39% 0.80x 1.42x CN¥1.01 Billion
2020 16.45% 20.72% 0.59x 1.35x CN¥500.89 Million
2021 18.86% 22.53% 0.63x 1.33x CN¥807.49 Million
2022 19.15% 24.13% 0.60x 1.32x CN¥1.04 Billion
2023 21.15% 29.24% 0.53x 1.36x CN¥1.49 Billion
2024 17.22% 31.58% 0.43x 1.26x CN¥1.06 Billion

Industry Comparison

This section compares Hubei Jumpcan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hubei Jumpcan Pharmaceutical Co Ltd (600566) CN¥13.86 Billion 9.80% 0.19x $1.21 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million